Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.
Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.
复制标题
DOI：
10.3390/jcm9123843
复制
发表时间：
2020-11-26
影响因子：
3.9
通讯作者：
Hoshida Y
中科院分区：
文献类型：
--
作者：
Kubota N;Fujiwara N;Hoshida Y
随着最近出现的肝细胞癌易感条件，即非酒精性脂肪肝和治愈的丙型肝炎病毒感染，肝细胞癌（HCC）风险的预测变得越来越重要。这些病因伴随着相对较低的HCC发病率（每年约1%或更低），同时影响大量患者人群。B型肝炎病毒感染仍然是一个主要的HCC危险因素，但大多数患者现在正在接受抗病毒治疗，这大大降低了，但不能消除，HCC的风险。因此，至关重要的是要识别出一小部分发展为HCC的可能性升高的患者，以优化有限的HCC筛查资源分配给最需要的患者，并实现具有成本效益的早期HCC诊断，以延长患者生存期。迄今为止，已经针对由肝病病因、严重程度和其他因素定义的特定临床背景开发了许多基于临床变量的HCC风险评分。同时，各种分子特征已被报道为潜在的HCC风险生物标志物，利用组织和体液标本。基于深度学习的风险建模是一种新兴的策略。虽然它们中没有一个被广泛纳入肝病患者的临床护理中，但有些已经经历了验证和临床开发的过程。在这篇综述中，这些风险评分和候选生物标志物进行了概述，并在其验证和临床翻译的战略问题进行了讨论。
Prediction of hepatocellular carcinoma (HCC) risk becomes increasingly important with recently emerging HCC-predisposing conditions, namely non-alcoholic fatty liver disease and cured hepatitis C virus infection. These etiologies are accompanied with a relatively low HCC incidence rate (~1% per year or less), while affecting a large patient population. Hepatitis B virus infection remains a major HCC risk factor, but a majority of the patients are now on antiviral therapy, which substantially lowers, but does not eliminate, HCC risk. Thus, it is critically important to identify a small subset of patients who have elevated likelihood of developing HCC, to optimize the allocation of limited HCC screening resources to those who need it most and enable cost-effective early HCC diagnosis to prolong patient survival. To date, numerous clinical-variable-based HCC risk scores have been developed for specific clinical contexts defined by liver disease etiology, severity, and other factors. In parallel, various molecular features have been reported as potential HCC risk biomarkers, utilizing both tissue and body-fluid specimens. Deep-learning-based risk modeling is an emerging strategy. Although none of them has been widely incorporated in clinical care of liver disease patients yet, some have been undergoing the process of validation and clinical development. In this review, these risk scores and biomarker candidates are overviewed, and strategic issues in their validation and clinical translation are discussed.
登录
查看更多内容
DOI：
10.1002/hep.29273
发表时间：
2017-10
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
BasuRay S;Smagris E;Cohen JC;Hobbs HH
通讯作者：
Hobbs HH
DOI：
10.1002/hep.28322
发表时间：
2016-02
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Burza MA;Motta BM;Mancina RM;Pingitore P;Pirazzi C;Lepore SM;Spagnuolo R;Doldo P;Russo C;Lazzaro V;Fischer J;Berg T;Aghemo A;Cheroni C;De Francesco R;Fargion S;Colombo M;Datz C;Stickel F;Valenti L;Romeo S
通讯作者：
Romeo S
影响因子：
13.5
作者：
Aleksandrova, Krasimira;Boeing, Heiner;Noethlings, Ute;Jenab, Mazda;Fedirko, Veronika;Kaaks, Rudolf;Lukanova, Annekatrin;Trichopoulou, Antonia;Trichopoulos, Dimitrios;Boffetta, Paolo;Trepo, Elisabeth;Westhpal, Sabine;Duarte-Salles, Talita;Stepien, Magdalena;Overvad, Kim;Tjonneland, Anne;Halkjaer, Jytte;Boutron-Ruault, Marie-Christine;Dossus, Laure;Racine, Antoine;Lagiou, Pagona;Bamia, Christina;Benetou, Vassiliki;Agnoli, Claudia;Palli, Domenico;Panico, Salvatore;Tumino, Rosario;Vineis, Paolo;Bueno-De-Mesquita, Bas;Peeters, Petra H.;Gram, Inger Torhild;Lund, Eiliv;Weiderpass, Elisabete;Quiros, J. Ramon;Agudo, Antonio;Sanchez, Maria-Jose;Gavrila, Diana;Barricarte, Aurelio;Dorronsoro, Miren;Ohlsson, Bodil;Lindkvist, Bjoern;Johansson, Anders;Sund, Malin;Khaw, Kay-Tee;Wareham, Nicholas;Travis, Ruth C.;Riboli, Elio;Pischon, Tobias
通讯作者：
Pischon, Tobias
影响因子：
13.5
作者：
Alonso Lopez, Sonia;Manzano, Maria Luisa;Banares, Rafael
通讯作者：
Banares, Rafael
影响因子：
4.6
作者：
Donati B;Dongiovanni P;Romeo S;Meroni M;McCain M;Miele L;Petta S;Maier S;Rosso C;De Luca L;Vanni E;Grimaudo S;Romagnoli R;Colli F;Ferri F;Mancina RM;Iruzubieta P;Craxi A;Fracanzani AL;Grieco A;Corradini SG;Aghemo A;Colombo M;Soardo G;Bugianesi E;Reeves H;Anstee QM;Fargion S;Valenti L
通讯作者：
Valenti L